Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer
- 1 January 2015
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 87 (1) , 23-27
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617.Journal of Clinical Oncology, 2013
- Prognostic Value of Whole-Body Total Lesion Glycolysis at Pretreatment FDG PET/CT in Non–Small Cell Lung CancerRadiology, 2012
- Defining Local-Regional Control and Its Importance in Locally Advanced Non-small Cell Lung CarcinomaJournal of Thoracic Oncology, 2012
- Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancerEuropean Journal of Nuclear Medicine and Molecular Imaging, 2011
- Sequential vs Concurrent Chemoradiation for Stage III Non-Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410JNCI: Journal of the National Cancer Institute, 2011
- Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2010
- Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trialThe Lancet, 2009
- Phase III Study of Cisplatin, Etoposide, and Concurrent Chest Radiation With or Without Consolidation Docetaxel in Patients With Inoperable Stage III Non–Small-Cell Lung Cancer: The Hoosier Oncology Group and U.S. OncologyJournal of Clinical Oncology, 2008
- Phase III Trial of Maintenance Gefitinib or Placebo After Concurrent Chemoradiotherapy and Docetaxel Consolidation in Inoperable Stage III Non–Small-Cell Lung Cancer: SWOG S0023Journal of Clinical Oncology, 2008
- Combined Chemoradiotherapy Regimens of Paclitaxel and Carboplatin for Locally Advanced Non–Small-Cell Lung Cancer: A Randomized Phase II Locally Advanced Multi-Modality ProtocolJournal of Clinical Oncology, 2005